Related Experiment Video
Updated: Jan 21, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled
Claudia Cosentino1, Ilaria Dicembrini1, Besmir Nreu1
1Diabetology, Careggi Hospital and University of Florence, Italy.
Abstract:
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) decreased serum uric acid in type 2 diabetes. Hyperuricemia is associated with an increased risk of nephrolithiasis. The present meta-analysis, performed on trials with duration ≥52 weeks in comparison with placebo or active comparators, suggests no effects of SGLT-2i on the risk of nephrolithiasis.
Insights
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) lower uric acid in type 2 diabetes. However, this meta-analysis found no increased risk of kidney stones (nephrolithiasis) with SGLT2i use in patients with type 2 diabetes.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are used to treat type 2 diabetes.
- SGLT2i have been observed to lower serum uric acid levels.
- Hyperuricemia is a known risk factor for nephrolithiasis (kidney stones).
Purpose of the Study:
- To evaluate the effect of SGLT2 inhibitors on the risk of nephrolithiasis.
- To analyze data from clinical trials comparing SGLT2i with placebo or active treatments.
Main Methods:
- Meta-analysis of randomized controlled trials.
- Included trials had a minimum duration of 52 weeks.
- Compared SGLT2 inhibitors against placebo or active comparators.
Main Results:
- SGLT2 inhibitors demonstrated a reduction in serum uric acid levels.
- The meta-analysis did not find a significant effect of SGLT2 inhibitors on the risk of nephrolithiasis.
- No increased incidence of kidney stones was observed with SGLT2i treatment.
Conclusions:
- Despite lowering uric acid, SGLT2 inhibitors do not appear to increase the risk of nephrolithiasis.
- SGLT2i can be safely used in type 2 diabetes patients, even those at risk for kidney stones.
- Further research may explore specific patient subgroups or long-term effects.
Related Concept Videos
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
2° Amines to N-Nitrosamines: Reaction with NaNO2
Secondary Active Transport
SN2 Reaction: Kinetics
In a chemical reaction, a relationship exists between the concentration of reactants and the rate at which the reaction proceeds. The study to measure this relationship is known as the kinetics of a chemical reaction. Kinetic studies are used to deduce the rate law of a chemical reaction, which provides information about the species involved during the transition state of the rate-determining step. Thus, kinetic studies help to derive the mechanism of a...
SN2 Reaction: Mechanism
The presence of the more electronegative halogen in the substrate creates a polarized carbon-halide bond. The halide pulls the electron cloud generating an electrophilic center at the carbon atom. Thus, the carbon atom carries a partial positive charge while the halide has a...

